To use one of the most popular words of 2024, this has been a “weird” year for medtech.
Analysis of Q1 – Q3 in 2024 show an uptick in deal activity from ‘23, including some fat M&A deals (hello J&J MedTech). At the same time, medtech companies laid off employees and put their spending on a diet.
I reported on all this excitement for MD+DI…the article will run in December. In the meantime, I share with you one of the reports I leaned on.
After doing my homework for that piece, and after a conversation with Kevin Saem, PhD, brand leader for Zapyrus, a medtech market intelligence firm, I am optimistic about 2025.
That optimism comes after a mediocre year for my business and for the businesses of some other talented colleagues. “Crap” is one way it was described.
I’m holding out hope because our economy is strong (for now) and because funding this year was strong (enough), among other reasons. Will the U.S. political climate throw a wrench is analysts’ predictions or the opposite? I’m not the one to answer that.
I tend to default to worry, so to keep my sanity, I’m going to focus on the positives this year has brought us, and the potential for what’s ahead.
What’s your outlook for 2025?
State of MedTech Q3 2024
Zapyrus released a detailed Q3 financial report. Give a read to find out why all the talk about lack of medtech funding isn’t entirely true, and what this year’s activity points to for 2025. Get the Insights.
The State of Healthcare Compliance
A recent report from Barnes & Thornburg sheds light on the challenges facing healthcare and life sciences compliance. Not enough (31%) feel “very prepared” to meet future compliance and risk challenges. They’re also short in resources and considering AI for certain functions. Review the Report
Want to be one of the first to get the monthly MedTech Marketing Minute delivered straight to your inbox? Sign up before the December issue drops: Get medtech marketing tips monthly